UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1724, 2026

	BIOCARDIA, INC.
	(Exact name of registrant as specified in its charter)

	Delaware		001-38999		23-2753988
	(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

	320 Soquel Way Sunnyvale, California 94085
	(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 82.0102. ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On March 1724, 2026, BioCardia, Inc. issued a press release announcing ~~that the FDA has accepted~~ its ~~pre-submission~~financial ~~package~~results for the ~~approval~~year ofended ~~its~~December ~~Helix~~31, ~~Transendocardial~~2025. ~~Delivery~~A ~~Catheter~~copy ~~(“Helix”)~~of ~~intended~~the ~~for~~press ~~intramyocardial~~release ~~therapeutic~~is ~~and~~furnished ~~diagnostic~~as ~~agent~~Exhibit ~~delivery~~99.1 to this report.

AThe ~~copy~~information ofin ~~the~~this ~~press~~Item ~~release~~2.02, isincluding the Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ~~Exhibit~~amended ~~99.1~~(the “Exchange Act”), or otherwise subject to ~~this~~the ~~current~~liabilities ~~report~~of onsuch ~~Form~~section, ~~8-K~~nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

The information in this Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1 104		BioCardia, Inc. press release dated March 17, 2026 Cover Page Interactive Data File (embedded within the Inline XBRL document)
99.1		BioCardia, Inc. press release dated March 24, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: March 1724, 2026

Filing Compare · BioCardia, Inc.